Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer

INTERPACE BIOSCIENCES, INC.

CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.
Severance of $127,500 (six months' base salary) payable over six months; equity awards scheduled to vest in 24 months fully accelerated.
Consulting fee of $6,000/month for up to 20% time (~8 hrs/week); term from Sept 30, 2022 to Jan 30–Mar 30, 2023.
Health and dental benefits continued for six months at Company expense; COBRA eligibility if elected.
Company actively recruiting a replacement CFO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas Freeburg

Chief Financial Officer

IDXG · INTERPACE BIOSCIENCES, INC.

Effective: 2022-09-30
Filed: October 4, 2022, 7:59 PM ET

On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. ( the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Freeburg resigned as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. ( the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company.

View on SEC.gov

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-027554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.